Citius Oncology grants Holubiak 300K stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Citius Oncology, Inc. (CTOR) reported option awards dated November 9, 2026, including 300,000 options granted to Secretary and director Myron Z. Holubiak and 50,000 options held by his daughter; Holubiak disclaims beneficial ownership of the latter. The options have an exercise price of $0.5495 per share and expire November 9, 2036.
The report also lists Holubiak’s existing options: 300,000 direct and 50,000 held by his daughter at $1.07 per share, expiring December 12, 2034, plus 1.5 million direct options at $2.15 per share, expiring July 5, 2033. He reported direct ownership of 850,000 common shares; 100,000 restricted stock awards are held by his daughter, and he disclaims beneficial ownership of those shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F2 | 300,000 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F2, F4 | 50,000 | $0.00 | $0.00 |
| Holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| Holding | Stock Option (Right to Buy) F3, F4 | -- | -- | -- |
| Holding | Stock Option (Right to Buy) F5 | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock F1 | -- | -- | -- |
Footnotes (5)
- F1. Represents restricted stock awards granted on September 19, 2025 to the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.
- F2. These options were granted on November 9, 2026. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
- F3. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
- F4. These options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.
- F5. These options vest over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
Key Figures
Key Terms
Continuous Service technical
restricted stock awards technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What options did CTOR report for Myron Z. Holubiak?
When do CTOR’s November 2026 options vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.